Medtronic Secures FDA Clearance for Stealth AXiS; Analysts Set $110.29 Price Target

Medtronic (NYSE: MDT) has secured U.S. Food and Drug Administration (FDA) clearance for its Stealth AXiS™ surgical system, a first-of-its-kind platform integrating planning, navigation, and robotics for spine procedures. The system utilizes LiveAlign™ technology to enable real-time tracking of anatomical motion, significantly reducing the need for intraoperative imaging. Following this regulatory milestone, analysts have established an average price target of $110.29 for MDT, signaling strong confidence in the company's growth trajectory. Despite this optimistic outlook, market observers note that the stock is currently trading at a premium valuation. This strategic launch within the AiBLE™ ecosystem is expected to bolster Medtronic's competitive edge in the rapidly expanding medical robotics sector. Investors are closely watching how this high-margin technology will impact the company's long-term financial performance and clinical outcomes.

Version History